Skip to main content

Figure 4. . CD3+/CD4+ lymphocyte counts highly correlate with overall survival in the ERC1671/bevacizumab treatment arm.

Figure 4. 

The maximal values, as well as end-of-treatment values, of CD3+/CD4+ mature helper/inducer T lymphocytes were determined in all patients from the ERC1671/bevacizumab group (A) and the placebo/bevacizumab group (B). Cell numbers were plotted over overall survival time.